Jpmorgan Chase & CO Milestone Pharmaceuticals Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Milestone Pharmaceuticals Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 3,266 shares of MIST stock, worth $5,421. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,266
Previous 900 262.89%
Holding current value
$5,421
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$0.8 - $2.41 $1,892 - $5,702
2,366 Added 262.89%
3,266 $2,000
Q4 2024

Feb 12, 2025
BUY
$1.43 - $2.36 $1,287 - $2,124
900 New
900 $2,000
Q4 2023

Dec 26, 2024
BUY
$1.67 - $3.39 $17,805 - $36,144
10,662 New
10,662 $17,000
Q4 2023

Feb 12, 2024
SELL
$1.67 - $3.39 $390,268 - $792,222
-233,694 Reduced 95.64%
10,662 $17,000
Q3 2023

Nov 14, 2023
SELL
$2.68 - $3.69 $7,522 - $10,357
-2,807 Reduced 1.14%
244,356 $757,000
Q2 2023

Aug 11, 2023
SELL
$2.85 - $4.4 $367,339 - $567,120
-128,891 Reduced 34.27%
247,163 $704,000
Q1 2023

May 11, 2023
BUY
$3.14 - $4.2 $145,476 - $194,586
46,330 Added 14.05%
376,054 $1.48 Million
Q4 2022

Feb 13, 2023
BUY
$3.53 - $9.5 $974,452 - $2.62 Million
276,049 Added 514.3%
329,724 $1.31 Million
Q3 2022

Nov 14, 2022
BUY
$5.86 - $9.43 $293,796 - $472,782
50,136 Added 1416.67%
53,675 $493,000
Q2 2022

Aug 11, 2022
SELL
$5.13 - $7.37 $51,510 - $74,002
-10,041 Reduced 73.94%
3,539 $21,000
Q1 2022

May 11, 2022
BUY
$4.1 - $8.24 $27,084 - $54,433
6,606 Added 94.72%
13,580 $87,000
Q4 2021

Feb 10, 2022
BUY
$5.47 - $7.13 $38,147 - $49,724
6,974 New
6,974 $46,000

Others Institutions Holding MIST

# of Institutions
50
Shares Held
16.9M
Call Options Held
71.8K
Put Options Held
34.8K
View Full List

About Milestone Pharmaceuticals Inc.

MIST Quotes by TradingView
  • Ticker MIST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,010,900
  • Market Cap $49.8M
  • Description
  • Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II cl...
More about MIST
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email